Related Experiment Videos
Antifungal agents in the 1990s. Current status and future developments
1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA. ckauff@umich.edu
Drugs
|April 1, 1997
Summary
Recent advances in antifungal therapy, particularly triazoles like itraconazole and fluconazole, offer effective treatments for various fungal infections. However, drug resistance and changing species patterns necessitate ongoing research into new agents and combination therapies.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Antifungal therapy has seen significant progress over the last decade.
- Advances are largely attributed to the introduction of triazole antifungals, itraconazole and fluconazole.
Purpose of the Study:
- To review the efficacy of current antifungal agents.
- To discuss emerging challenges such as drug resistance.
- To highlight new developments in antifungal drug discovery.
Main Methods:
- Review of recent clinical trials and therapeutic guidelines.
- Analysis of epidemiological shifts in fungal pathogens.
- Evaluation of new antifungal agents in early trials.
Main Results:
- Itraconazole is effective for endemic mycoses and Aspergillus infections.
- Fluconazole is standard for candidiasis and coccidioidal meningitis.
- Amphotericin B remains crucial for life-threatening infections, with lipid formulations reducing nephrotoxicity.
- Emergence of drug resistance and shifts in yeast species are noted, particularly in AIDS patients.
Conclusions:
- Triazoles have expanded treatment options for fungal infections.
- Amphotericin B and its formulations are vital for severe cases.
- Addressing drug resistance and exploring combination therapies are key future directions.